Publication | Open Access

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

Non-small-cell Lung CancerMedicinePharmacologyPathologyCancer Cell BiologyBronchial NeoplasmCancer TreatmentMek1/mek2 Inhibitor TrametinibOncologyRadiation OncologyLung CancerMolecular OncologyCancer Growth